Skip to navigation Skip to content



A Positive Review Brings Daclizumab a Step Closer to Approval in Europe for Treating Relapsing MS

May 2, 2016

Daclizumab (proposed brand name: ZinbrytaTM, being developed by Biogen and AbbVie) has passed a regulatory hurdle as part of its review by the European Medicines Agency (EMA) for possible approval for relapsing forms of multiple sclerosis. This compound, taken every four weeks by subcutaneous (under the skin) injection, is also under review by other regulatory authorities including the U.S. Food and Drug Administration.

Read about its recommendation and future steps on the EMA's Website
Read about current treatment options for MS

About Multiple Sclerosis

Multiple sclerosis is an unpredictable, often disabling disease of the central nervous system that disrupts the flow of information within the brain, and between the brain and body. Symptoms range from numbness and tingling to blindness and paralysis. The progress, severity and specific symptoms of MS in any one person cannot yet be predicted, but advances in research and treatment are leading to better understanding and moving us closer to a world free of MS. Most people with MS are diagnosed between the ages of 20 and 50, with at least two to three times more women than men being diagnosed with the disease. MS affects more than 2.3 million people worldwide.


© 2020 The National Multiple Sclerosis Society is a tax exempt 501(c)3 nonprofit organization and our Identification Number (EIN) is 13-5661935.